Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Journal of Clinical Oncology|2018Cited by 103
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Blood|2016Cited by 9
Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.Andrew M. Evens, Nancy L. Bartlett, Mint Sirisawad et al.|Blood|2009Cited by 8
CBFβ-SMMHC Inactivates p53 Tumor Suppressor Through Aberrant Protein Interaction and Recruitment of HDAC8Jing Qi, Ya‐Huei Kuo, Sandeep Singh et al.|Blood|2012Cited by 0